Sfoglia per Autore
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity
2000-01-01 L. TRUSOLINO; S. CAVASSA; P. ANGELINI; M. ANDO'; A. BERTOTTI; P. COMOGLIO; C. BOCCACCIO
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth.
2001-01-01 L. TRUSOLINO; A. BERTOTTI; P.M. COMOGLIO
Tyrosine kinase signal specificity: lessons from the HGF receptor.
2003-01-01 BERTOTTI A; PM COMOGLIO
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
2005-01-01 Bertotti A; Comoglio PM; Trusolino L
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
2006-01-01 Bertotti A; Comoglio PM; Trusolino L
Met-driven invasive growth involves transcriptional regulation of Arhgap12
2008-01-01 Gentile A; D'Alessandro L; Lazzari L; Martinoglio B; Bertotti A; Mira A; Lanzetti L; Comoglio PM; Medico E.
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma
2009-01-01 Raffaella De Maria; Silvia Miretti; Selina Iussich; Martina Olivero;Emanuela Morello; Andrea Bertotti; James G. Christensen; Bartolomeo Biolatti; Roy A. Levine; Paolo Buracco; Maria Flavia Di Renzo
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective
2009-01-01 Gastaldi S; Bertotti A; Bracco C; Galimi F; Torti D; Trusolino L
Only a subset of Met-activated pathways are required to sustain oncogene addiction
2009-01-01 Bertotti A; Burbridge MF; Gastaldi S; Galimi F; Torti D; Medico E; Giordano S; Corso S; Rolland-Valognes G; Lockhart BP; Hickman JA; Comoglio PM; Trusolino L.
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents
2009-01-01 Albero Rocci; Francesca Gay; Livio Trusolino; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Milena Gilestro; Anna M. Liberati; Fausto Rossini; Tommaso Caravita; Antonietta Falcone; Giuseppe Rossi; Daniela Drandi; Paolo Corradini; Marco Ladetto; Paolo M. Comoglio; Mario Boccadoro; Antonio Palumbo
Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma
2009-01-01 De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF.
Met as a potential therapeutic target in basal-like breast cancer
2010-01-01 Gastaldi S; Bertotti A; Galimi F; Sassi F; Torti D; Smalley M; Trusolino L
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease
2010-01-01 Alberto Rocci; Manuela Gambella; Simona Aschero; Ileana Baldi; Livio Trusolino; Federica Cavallo; Alessandra Larocca; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Anna Marina Liberati; Antonietta Falcone; Gianluca Isaia; Daniela Drandi; Marco Ladetto; Paolo M. Comoglio; Giovannino Ciccone; Mario Boccadoro; and Antonio Palumbo
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition
2010-01-01 Torti D; Bertotti A; Galimi F; Gastaldi S; Sassi F; Trusolino L
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS
2010-01-01 Rocci A; Gambella M; Trusolino L; Gay F; Omedè P; Magarotto V; Bertotti A; Montefusco V; Crippa C; Patriarca F; Gilestro M; Liberati AM; Gaidano G; Di Raimondo F; Falcone A; Rossi G; Drandi D; Corradini P; Ladetto M; Comoglio PM; Boccadoro M; Palumbo A
Inhibition of Src impairs the growth of met-addicted gastric tumors.
2010-01-01 A. Bertotti;C. Bracco;F. Girolami;D. Torti;S. Gastaldi;F. Galimi;E. Medico;P. Elvin;P. M. Comoglio;L. Trusolino
MET signalling: principles and functions in development, organ regeneration and cancer.
2010-01-01 Trusolino L; Bertotti A; Comoglio PM
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth
2010-01-01 Franco M; Muratori C; Corso S; Tenaglia E; Bertotti A; Capparuccia L; Trusolino L; Comoglio PM; Tamagnone L.
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
2010-01-01 S. Corso;E. Ghiso;V. Cepero;J. R. Sierra;C. Migliore;A. Bertotti;L. Trusolino;P. M. Comoglio;S. Giordano
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice.
2010-01-01 Casazza A; Finisguerra V; Capparuccia L; Camperi A; Swiercz JM; Rizzolio S; Rolny C; Christensen C; Bertotti A; Sarotto I; Risio M; Trusolino L; Weitz J; Schneider M; Mazzone M; Comoglio PM; Tamagnone L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity | 2000 | L. TRUSOLINO; S. CAVASSA; P. ANGELINI; M. ANDO'; A. BERTOTTI; P. COMOGLIO; C. BOCCACCIO | |
| A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. | 2001 | L. TRUSOLINO; A. BERTOTTI; P.M. COMOGLIO | |
| Tyrosine kinase signal specificity: lessons from the HGF receptor. | 2003 | BERTOTTI A; PM COMOGLIO | |
| beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. | 2005 | Bertotti A; Comoglio PM; Trusolino L | |
| Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. | 2006 | Bertotti A; Comoglio PM; Trusolino L | |
| Met-driven invasive growth involves transcriptional regulation of Arhgap12 | 2008 | Gentile A; D'Alessandro L; Lazzari L; Martinoglio B; Bertotti A; Mira A; Lanzetti L; Comoglio PM; Medico E. | |
| met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma | 2009 | Raffaella De Maria; Silvia Miretti; Selina Iussich; Martina Olivero;Emanuela Morello; Andrea Bertotti; James G. Christensen; Bartolomeo Biolatti; Roy A. Levine; Paolo Buracco; Maria Flavia Di Renzo | |
| Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective | 2009 | Gastaldi S; Bertotti A; Bracco C; Galimi F; Torti D; Trusolino L | |
| Only a subset of Met-activated pathways are required to sustain oncogene addiction | 2009 | Bertotti A; Burbridge MF; Gastaldi S; Galimi F; Torti D; Medico E; Giordano S; Corso S; Rolland-Valognes G; Lockhart BP; Hickman JA; Comoglio PM; Trusolino L. | |
| Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents | 2009 | Albero Rocci; Francesca Gay; Livio Trusolino; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Milena Gilestro; Anna M. Liberati; Fausto Rossini; Tommaso Caravita; Antonietta Falcone; Giuseppe Rossi; Daniela Drandi; Paolo Corradini; Marco Ladetto; Paolo M. Comoglio; Mario Boccadoro; Antonio Palumbo | |
| Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma | 2009 | De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF. | |
| Met as a potential therapeutic target in basal-like breast cancer | 2010 | Gastaldi S; Bertotti A; Galimi F; Sassi F; Torti D; Smalley M; Trusolino L | |
| High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease | 2010 | Alberto Rocci; Manuela Gambella; Simona Aschero; Ileana Baldi; Livio Trusolino; Federica Cavallo; Alessandra Larocca; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Anna Marina Liberati; Antonietta Falcone; Gianluca Isaia; Daniela Drandi; Marco Ladetto; Paolo M. Comoglio; Giovannino Ciccone; Mario Boccadoro; and Antonio Palumbo | |
| Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition | 2010 | Torti D; Bertotti A; Galimi F; Gastaldi S; Sassi F; Trusolino L | |
| EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS | 2010 | Rocci A; Gambella M; Trusolino L; Gay F; Omedè P; Magarotto V; Bertotti A; Montefusco V; Crippa C; Patriarca F; Gilestro M; Liberati AM; Gaidano G; Di Raimondo F; Falcone A; Rossi G; Drandi D; Corradini P; Ladetto M; Comoglio PM; Boccadoro M; Palumbo A | |
| Inhibition of Src impairs the growth of met-addicted gastric tumors. | 2010 | A. Bertotti;C. Bracco;F. Girolami;D. Torti;S. Gastaldi;F. Galimi;E. Medico;P. Elvin;P. M. Comoglio;L. Trusolino | |
| MET signalling: principles and functions in development, organ regeneration and cancer. | 2010 | Trusolino L; Bertotti A; Comoglio PM | |
| The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth | 2010 | Franco M; Muratori C; Corso S; Tenaglia E; Bertotti A; Capparuccia L; Trusolino L; Comoglio PM; Tamagnone L. | |
| Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. | 2010 | S. Corso;E. Ghiso;V. Cepero;J. R. Sierra;C. Migliore;A. Bertotti;L. Trusolino;P. M. Comoglio;S. Giordano | |
| Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. | 2010 | Casazza A; Finisguerra V; Capparuccia L; Camperi A; Swiercz JM; Rizzolio S; Rolny C; Christensen C; Bertotti A; Sarotto I; Risio M; Trusolino L; Weitz J; Schneider M; Mazzone M; Comoglio PM; Tamagnone L. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile